Crossmark

Ritlecitinib: Efficacy of a Novel Therapy for Severe Alopecia Areata in Patients Aged 12 Years and Older

Crossref DOI link: https://doi.org/10.1016/j.ad.2025.104487

Published Print: 2026-01

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Vañó-Galván, S.

Figueras-Nart, I.

Serrano, C.

Fortes, M.P. https://orcid.org/0000-0002-2412-154X
Herrera-Lasso, V.

Botella-Estrada, R.
Funding

Funding for this research was provided by:

Pfizer
License Information

Text and Data Mining valid from 2026-01-01

Text and Data Mining valid from 2026-01-01

Version of Record valid from 2025-12-02
More Information

This article is maintained by: Elsevier

Article Title: Ritlecitinib: Efficacy of a Novel Therapy for Severe Alopecia Areata in Patients Aged 12 Years and Older

Journal Title: Actas Dermo-Sifiliográficas

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.ad.2025.104487

Content Type: article

Copyright: © 2025 Published by Elsevier España, S.L.U. on behalf of AEDV.